Systematic and MRI-Cognitive Targeted Transperineal Prostate Biopsy Accuracy in Detecting Clinically Significant Prostate Cancer after Previous Negative Biopsy and Persisting Suspicion of Malignancy

• Published in: Medicina (Kaunas, Lithuania) Lithuania), 2021-01, Vol.57 (1), p.57
• Main Authors: Vėželis, Alvydas, Platkevičius, Gediminas, Kinčius, Marius, Gumbys, Liutauras, Naruševičiūtė, Ieva, Briedienė, Rūta, Petroška, Donatas, Ulys, Albertas, Jankevičius, Feliksas
• Format: Article
• Language: English
• Subjects: Adenocarcinoma - diagnosis; Adenocarcinoma - metabolism; Adenocarcinoma - pathology; Aged; Biopsy, Large-Core Needle - methods; cognitive targeted prostate biopsy; Cohort Studies; Humans; Image-Guided Biopsy - methods; Magnetic Resonance Imaging; Male; Middle Aged; multi-parametric magnetic resonance imaging; Multiparametric Magnetic Resonance Imaging; Neoplasm Grading; Perineum; Prospective Studies; Prostate - pathology; prostate cancer; Prostate-Specific Antigen - metabolism; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; transperineal prostate biopsy
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina57010057

Overdiagnosis, overtreatment, and the need for repeated procedures caused by transrectal ultrasound guided prostate biopsies and their related complications places a heavy burden on healthcare systems. This was a prospective cohort validating study to access the clinical accuracy of systematic and MRI-cognitive targeted transperineal prostate biopsies in detecting clinically significant prostate cancer after a previous negative biopsy and persistent suspicion of malignancy. The primary goal was to assess the ability of multiparametric magnetic resonance imaging (mpMRI) to detect clinically significant prostate cancer with an additional goal to assess the diagnostic value of systematic and MRI-cognitive transperineal biopsies. In total, 200 patients were enrolled who had rising serum prostate specific antigen (PSA) levels for at least 4 months after a previous negative transrectal ultrasound (TRUS) biopsy. All eligible men underwent 1.5T prostate mpMRI, reported using the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2), followed by a 20-region transperineal prostate systematic biopsy and additional targeted biopsies. Systematic 20-core transperineal prostate biopsies (TPBs) were performed for 38 (19%) patients. Systemic 20-core TPB with additional cognitive targeted biopsies were performed for 162 (81%) patients. Clinically significant prostate cancer (csPC) was detected for 31 (15.5%) patients, of which 20 (64.5%) cases of csPC were detected by systematic biopsy, eight (25.8%) cases were detected by targeted biopsy, and three (9.7%) both by systematic and targeted biopsies. Cognitive mpMRI guided transperineal target biopsies increase the detection rate of clinically significant prostate cancer after a previously negative biopsy. However, in a repeat prostate biopsy setting, we recommend applying a cognitive targeted biopsy with the addition of a systematic biopsy.